Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study

BACKGROUND: Immune checkpoint inhibitors (ICI) have led to a prolongation of progression-free and overall survival in patients with metastatic Merkel cell carcinoma (MCC). However, immune-mediated adverse events due to ICI therapy are common and often lead to treatment discontinuation. The response...

Descripción completa

Detalles Bibliográficos
Autores principales: Stege, H. M., Haist, M., Schultheis, S., Fleischer, M. I., Mohr, P., Ugurel, S., Terheyden, P., Thiem, A., Kiecker, F., Leiter, U., Becker, J. C., Meissner, M., Kleeman, J., Pföhler, C., Hassel, J., Grabbe, S., Loquai, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505278/
https://www.ncbi.nlm.nih.gov/pubmed/33870464
http://dx.doi.org/10.1007/s00262-021-02925-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505278/
https://www.ncbi.nlm.nih.gov/pubmed/33870464
http://dx.doi.org/10.1007/s00262-021-02925-4

Ejemplares similares